CLARENDON HOUSE, HAMILTON, D0
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
Ross Moat Appointed Chief Operating Officer at Kiniksa Pharmaceuticals
Provides Corporate Update
Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
Reg. FD
Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
Presentation JUNE 2025
Shareholder votes
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Certification of Termination of Registration of a Class of Security
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence